arrow
E

Erik Hooijberg

Maastricht University
H指数:39
被引数:4,861

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma
2024-11-080
OA
Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
2023-07-141
OAAI
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk
2022-06-299
OA
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
2021-12-22151
OAAI
The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer

尿路上皮癌的肿瘤免疫景观和三级淋巴结构的结构

2021-12-2025
OAAI
Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ

乳腺脂肪细胞大小与导管原位癌后同侧浸润性乳腺癌风险相关

2021-03-2215
OAAI
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
2020-10-12261
PREAI
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy

随机接受辅助强化铂类化疗与常规化疗的III期乳腺癌患者的肿瘤浸润淋巴细胞 (til) 和BRCA样状态

2020-03-0123
PREAI
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival
2018-09-1189
OAAI
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells
2017-10-2077
OAAI
PD-L1 positive tumor-infiltrating lymphocytes and mutational load in breast cancer
2017-07-010
PRE